MULTICENTER, NON-COMMERCIAL PHASE II CLINICAL TRIAL
In the Treatment of Advanced, Progressive Adrenocortical Carcinoma
We invite you to participate in a multicenter, non-commercial, non-randomized phase II clinical trial aimed at assessing the efficacy and tolerability of pembrolizumab in patients with advanced, inoperable, or metastatic progressive adrenocortical carcinoma after chemotherapy.
If you need assistance, please contact:
BioStat Sp. z o.o.
Kowalczyka 17, 44-206 Rybnik
Phone: 570 589 664
Email: [email protected]
This project is funded
by the Agency for Medical Research.